1
|
Mazzella A, Orlandi R, Maiorca S, Uslenghi C, Chiari M, Bertolaccini L, Casiraghi M, Lo Iacono G, Girelli L, Spaggiari L. How General and Inflammatory Status Impacts on the Prognosis of Patients Affected by Lung Cancer: State of the Art. Biomedicines 2024; 12:1554. [PMID: 39062127 PMCID: PMC11274951 DOI: 10.3390/biomedicines12071554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2024] [Revised: 06/23/2024] [Accepted: 07/09/2024] [Indexed: 07/28/2024] Open
Abstract
Pulmonary cancer is often associated with systemic inflammation and poor nutritional status and these two aspects are strongly correlated and related to the scarce infiltration of a tumor by immune cells. We reviewed all English literature reviews from 2000 to 2024 from PubMed, Scopus and Google Scholar, including original articles, review articles, and metanalyses. We excluded non-English language articles and case reports/case series. Generally speaking, nutritional and inflammatory status largely affect medium and long-term prognosis in lung cancer patients. A correct stratification of patients could improve their preoperative general functional nutritional and inflammatory status, minimizing, therefore, possible treatment complications and improving long-term prognosis.
Collapse
Affiliation(s)
- Antonio Mazzella
- Division of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; (R.O.); (S.M.); (C.U.); (M.C.); (L.B.); (M.C.); (G.L.I.); (L.G.); (L.S.)
| | - Riccardo Orlandi
- Division of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; (R.O.); (S.M.); (C.U.); (M.C.); (L.B.); (M.C.); (G.L.I.); (L.G.); (L.S.)
| | - Sebastiano Maiorca
- Division of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; (R.O.); (S.M.); (C.U.); (M.C.); (L.B.); (M.C.); (G.L.I.); (L.G.); (L.S.)
| | - Clarissa Uslenghi
- Division of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; (R.O.); (S.M.); (C.U.); (M.C.); (L.B.); (M.C.); (G.L.I.); (L.G.); (L.S.)
| | - Matteo Chiari
- Division of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; (R.O.); (S.M.); (C.U.); (M.C.); (L.B.); (M.C.); (G.L.I.); (L.G.); (L.S.)
| | - Luca Bertolaccini
- Division of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; (R.O.); (S.M.); (C.U.); (M.C.); (L.B.); (M.C.); (G.L.I.); (L.G.); (L.S.)
| | - Monica Casiraghi
- Division of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; (R.O.); (S.M.); (C.U.); (M.C.); (L.B.); (M.C.); (G.L.I.); (L.G.); (L.S.)
| | - Giorgio Lo Iacono
- Division of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; (R.O.); (S.M.); (C.U.); (M.C.); (L.B.); (M.C.); (G.L.I.); (L.G.); (L.S.)
| | - Lara Girelli
- Division of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; (R.O.); (S.M.); (C.U.); (M.C.); (L.B.); (M.C.); (G.L.I.); (L.G.); (L.S.)
| | - Lorenzo Spaggiari
- Division of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; (R.O.); (S.M.); (C.U.); (M.C.); (L.B.); (M.C.); (G.L.I.); (L.G.); (L.S.)
- Division of Oncology and Hemato-Oncology, University of Milan, 20141 Milan, Italy
| |
Collapse
|
2
|
Mazzella A, Maiolino E, Maisonneuve P, Loi M, Alifano M. Systemic Inflammation and Lung Cancer: Is It a Real Paradigm? Prognostic Value of Inflammatory Indexes in Patients with Resected Non-Small-Cell Lung Cancer. Cancers (Basel) 2023; 15:cancers15061854. [PMID: 36980740 PMCID: PMC10046843 DOI: 10.3390/cancers15061854] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2023] [Revised: 03/16/2023] [Accepted: 03/18/2023] [Indexed: 03/30/2023] Open
Abstract
Background (1): Our goal was to investigate if and how pre-operative inflammatory status can influence the long-term prognosis of patients undergoing lung surgery for cancer. Materials and Methods (2): This prospective observational study includes the agreement of all operable patients to the study, who were referred to our department between 1 January 2017 and 30 December 2018. The inflammatory pre-operative status of the patients was investigated by calculating albumin, CPR (c-protein reactive), complete blood count (neutrophils, lymphocytes, platelets, hemoglobin), and some other indexes referring to inflammatory status, namely the HALP amalgamated index, platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocytes ratio (NLR), systemic immune-inflammation index (SII), and advanced lung cancer inflammation Index (ALI). The follow-up ended in November 2021. Patient overall survival was assessed using the Kaplan-Meier method. The log-rank test was used to compare survival rates. Variables significantly associated with survival at univariate analysis were entered int Cox multivariate analysis (stepwise mode) to assess their independent character. Hazard ratios and their 95% confidence intervals were calculated. Variables associated with p < 0.05 were considered significative. Results (3): We enrolled 257 patients in our study. The overall survival of the cohort was as follows: 1 year, 96.1%; 3 year, 81.3%; and 4 year, 74.2%. Univariate analysis showed risk factors for overall survival as follows: Thoracoscore ≥ 2 (p = 0.002); histology (p = 0.002); HALP < 32.2 (p = 0.0002); SII ≥ 808.9 (p = 0.0004); ALI < 34.86 (p = 0.0005); NLr ≥ 2.29 (p = 0.01); hemoglobin < 13 g/dl (p = 0.01); PLR ≥ 196.1 (p = 0.005); pN+ (p < 0.0001); pleural invasion (p = 0.0002); and presence of vascular or lymphatic tumor emboli (p = 0.0002). Multivariate Cox analysis (stepwise model) identified Thoracoscore ≥ 2 (p = 0.02); histology, HALP < 32.2 (p = 0.004), and pN (p < 0.0001) as independent predictors of death. Conclusion (4): Pre-operative inflammatory status strongly influences long-term prognosis in patients affected by NSCLC and undergoing surgery.
Collapse
Affiliation(s)
- Antonio Mazzella
- Thoracic Surgical Department, Cochin Academic Hospital, APHP, Université de Paris, 75014 Paris, France
| | - Elena Maiolino
- Thoracic Surgical Department, Cochin Academic Hospital, APHP, Université de Paris, 75014 Paris, France
| | - Patrick Maisonneuve
- Division of Epidemiology and Biostatistics, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy
| | - Mauro Loi
- Thoracic Surgical Department, Cochin Academic Hospital, APHP, Université de Paris, 75014 Paris, France
| | - Marco Alifano
- Thoracic Surgical Department, Cochin Academic Hospital, APHP, Université de Paris, 75014 Paris, France
| |
Collapse
|
3
|
Wang G, Kang B, Cui J, Deng Y, Zhao Y, Ji C, Wang X. Two nomograms based on radiomics models using triphasic CT for differentiation of adrenal lipid-poor benign lesions and metastases in a cancer population: an exploratory study. Eur Radiol 2023; 33:1873-1883. [PMID: 36264313 DOI: 10.1007/s00330-022-09182-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2022] [Revised: 09/13/2022] [Accepted: 09/19/2022] [Indexed: 12/07/2022]
Abstract
OBJECTIVES To investigate the effectiveness of CT-based radiomics nomograms in differentiating adrenal lipid-poor benign lesions and metastases in a cancer population. METHODS This retrospective study enrolled 178 patients with cancer history from three medical centres categorised as those with adrenal lipid-poor benign lesions or metastases. Patients were divided into training, validation, and external testing cohorts. Radiomics features were extracted from triphasic CT images (unenhanced, arterial, and venous) to establish three single-phase models and one triphasic radiomics model using logistic regression. Unenhanced and triphasic nomograms were established by incorporating significant clinico-radiological factors and radscores. The models were evaluated by the receiver operating characteristic curve, Delong's test, calibration curve, and decision curve. RESULTS Lesion side, diameter, and enhancement ratio resulted as independent factors and were selected into nomograms. The areas under the curves (AUCs) of unenhanced and triphasic radiomics models in validation (0.878, 0.914, p = 0.381) and external testing cohorts (0.900, 0.893, p = 0.882) were similar and higher than arterial and venous models (validation: 0.842, 0.765; testing: 0.814, 0.806). Unenhanced and triphasic nomograms yielded similar AUCs in validation (0.903, 0.906, p = 0.955) and testing cohorts (0.928, 0.946, p = 0.528). The calibration curves showed good agreement and decision curves indicated satisfactory clinical benefits. CONCLUSION Unenhanced and triphasic CT-based radiomics nomograms resulted as a useful tool to differentiate adrenal lipid-poor benign lesions from metastases in a cancer population. They exhibited similar predictive efficacies, indicating that enhanced examinations could be avoided in special populations. KEY POINTS • All four radiomics models and two nomograms using triphasic CT images exhibited favourable performances in three cohorts to characterise the cancer population's adrenal benign lesions and metastases. • Unenhanced and triphasic radiomics models had similar predictive performances, outperforming arterial and venous models. • Unenhanced and triphasic nomograms also exhibited similar efficacies and good clinical benefits, indicating that contrast-enhanced examinations could be avoided when identifying adrenal benign lesions and metastases.
Collapse
Affiliation(s)
- Gongzheng Wang
- Department of Radiology, Shandong Provincial Hospital, Shandong University, Jinan, 250021, Shandong, China
| | - Bing Kang
- Department of Radiology, Shandong Provincial Hospital, Shandong University, Jinan, 250021, Shandong, China
| | - Jingjing Cui
- United Imaging Intelligence (Beijing) Co., Ltd., Beijing, 100094, China
| | - Yan Deng
- Department of Radiology, Qilu Hospital of Shandong University, Jinan, 250012, Shandong, China
| | - Yun Zhao
- Department of Radiology, Qilu Hospital of Shandong University, Jinan, 250012, Shandong, China
| | - Congshan Ji
- Department of Radiology, Shandong Provincial Hospital, Shandong University, Jinan, 250021, Shandong, China. .,Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, Shandong, China.
| | - Ximing Wang
- Department of Radiology, Shandong Provincial Hospital, Shandong University, Jinan, 250021, Shandong, China. .,Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, Shandong, China.
| |
Collapse
|
4
|
Recurrence patterns and impact of brain metastases in synchronous single organ oligometastatic lung cancer following local ablative treatment – A multicenter analysis. Lung Cancer 2022; 170:165-175. [DOI: 10.1016/j.lungcan.2022.06.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2022] [Revised: 06/20/2022] [Accepted: 06/26/2022] [Indexed: 11/21/2022]
|
5
|
Yajima S, Nakanishi Y, Matsumoto S, Tanabe K, Tsuboi M, Masuda H. Prognostic significance of the postoperative/preoperative serum CEA level ratio in patients with solitary adrenal metastasis from lung cancer. Mol Clin Oncol 2021; 16:10. [PMID: 34881030 DOI: 10.3892/mco.2021.2443] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2021] [Accepted: 10/06/2021] [Indexed: 01/26/2023] Open
Abstract
The present study aimed to evaluate the prognostic significance of the postoperative to preoperative serum carcinoembryonic antigen (CEA) level ratio (CEA ratio) in patients with lung cancer with solitary metastasis of the adrenal gland after adrenalectomy. Furthermore, the optimal CEA ratio cutoff value for predicting disease-free survival (DFS) in patients with lung cancer after adrenalectomy was determined. The medical records of patients with lung cancer with isolated adrenal metastasis who underwent adrenalectomy at the National Cancer Center Hospital East (Kashiwa, Japan) between January 2013 and December 2020 were retrospectively reviewed. Receiver operating characteristic curve analysis was used to segregate patients into two groups (high and low CEA groups) and the clinical prognosis for the two groups was determined. In addition, the association between the CEA ratio and clinical factors was determined. A total of 14 patients with a median age of 68 years (range, 50-75 years) were analyzed, of which 9 (64%) were males. The optimal cutoff value for the CEA ratio to predict DFS was 0.60. The high CEA ratio group (≥0.60) displayed poorer DFS and cancer-specific survival (P=0.03 and 0.02, respectively). The CEA ratio was significantly associated with the preoperative CEA level (P=0.01) and the high CEA ratio (≥0.60) group had lower preoperative CEA levels. The study suggested that the perioperative CEA ratio may be an important emerging prognostic factor for patients with lung cancer with solitary adrenal gland metastasis. As the sample size was limited, a further study with a larger cohort is required to validate the present findings.
Collapse
Affiliation(s)
- Shugo Yajima
- Department of Urology, National Cancer Center Hospital East, Kashiwa, Chiba 277-8577, Japan
| | - Yasukazu Nakanishi
- Department of Urology, National Cancer Center Hospital East, Kashiwa, Chiba 277-8577, Japan
| | - Shunya Matsumoto
- Department of Urology, National Cancer Center Hospital East, Kashiwa, Chiba 277-8577, Japan
| | - Kenji Tanabe
- Department of Urology, National Cancer Center Hospital East, Kashiwa, Chiba 277-8577, Japan
| | - Masahiro Tsuboi
- Department of Pulmonology, National Cancer Center Hospital East, Kashiwa, Chiba 277-8577, Japan
| | - Hitoshi Masuda
- Department of Urology, National Cancer Center Hospital East, Kashiwa, Chiba 277-8577, Japan
| |
Collapse
|
6
|
Eichhorn F, Winter H. How to handle oligometastatic disease in nonsmall cell lung cancer. Eur Respir Rev 2021; 30:30/159/200234. [PMID: 33650527 DOI: 10.1183/16000617.0234-2020] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2020] [Accepted: 10/07/2020] [Indexed: 12/27/2022] Open
Abstract
Patients with nonsmall cell lung cancer and limited metastatic disease have been defined as oligometastatic if local ablative therapy of all lesions is amenable. Evidence from different clinical retrospective series suggests that this subgroup harbours better prognosis than other stage IV patients. However, most reports have included patients with inconsistent numbers of metastases in different locations treated by a variety of invasive and noninvasive therapies. As long as further results from randomised clinical trials are awaited, treatment decision follows an interdisciplinary debate in each individual case. Surgery and radiotherapy should capture a dominant role in the treatment course offering the option of a curative-intended local therapy in combination with a systemic therapy based on an interdisciplinary decision. This review summarises the current treatment standard in oligometastatic lung cancer with focus on an ablative therapy for both lung primary and distant metastases in prognostically favourable locations.
Collapse
Affiliation(s)
- Florian Eichhorn
- Dept of Thoracic Surgery, Thoraxklinik, University Hospital Heidelberg, Heidelberg, Germany.,Translational Lung Research Center (TLRC), Member of the German Center for Lung Research (DZL), Heidelberg, Germany
| | - Hauke Winter
- Dept of Thoracic Surgery, Thoraxklinik, University Hospital Heidelberg, Heidelberg, Germany .,Translational Lung Research Center (TLRC), Member of the German Center for Lung Research (DZL), Heidelberg, Germany
| |
Collapse
|
7
|
Mușină AM, Huțanu I, Scripcariu DV, Aniței MG, Filip B, Hogea M, Radu I, Gavrilescu MM, Panuță A, Buna-Arvinte M, Moraru VG, Scripcariu V. SURGICAL MANAGEMENT OF THE ADRENAL GLAND TUMORS - SINGLE CENTER EXPERIENCE. ACTA ENDOCRINOLOGICA-BUCHAREST 2020; 16:208-215. [PMID: 33029238 DOI: 10.4183/aeb.2020.208] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Context Incidentally discovered solid adrenal tumors must be evaluated from two points of view: the risk of malignancy and the secretory feature. Objective Our aim was to evaluate the surgical technique option in relation with clinical and histopathologic features. Design We performed a retrospective study that included patients with adrenal gland tumors. Subjects and methods All patients were operated between 2012 and 2019 by the same surgical team in a single center. Results The batch included 102 patients with adrenal tumors operated through open surgery (OS, n=41) and laparoscopic surgery (LS, n=61). Tumor localization was especially on the right adrenal gland (n=52, 50.98%). Primary origin of the adrenal gland tumors was in 82 cases (80.39%) and a metastatic origin in 16 cases. Average dimension for surgical resected tumors was 4.02 cm (0.9-12 cm) for the LS group as compared to 7.22 cm (1.3-19 cm) for OS group with a predominant type of surgery represented by adrenalectomy and a conversion rate of 2.94%. The hospital stay was 7.22 days (5-12 days) in the LS group versus 12.72 days (6-57 days) in OS group with significant differences (p<0.01). Also, the postoperative recovery was significantly different (6.5 days versus 2.62 days, p<0.01). Conclusion Laparoscopic approach represents the gold standard in adrenal gland tumors less than five centimeters in size. Adrenalectomy is mostly performed by LS and adenoma is the most frequent histopathologic type, while pheochromocytoma is operated through OS. LS has a significantly reduced hospitalization and postoperative stay compared to OS.
Collapse
Affiliation(s)
- A M Mușină
- "Grigore T. Popa" University of Medicine and Pharmacy - Surgical Department, Iasi, Romania.,Regional Institute of Oncology Iasi - 1 Surgical Oncology Unit, Iasi, Romania
| | - I Huțanu
- "Grigore T. Popa" University of Medicine and Pharmacy - Surgical Department, Iasi, Romania.,Regional Institute of Oncology Iasi - 1 Surgical Oncology Unit, Iasi, Romania
| | - D V Scripcariu
- "Grigore T. Popa" University of Medicine and Pharmacy - Surgical Department, Iasi, Romania.,Regional Institute of Oncology Iasi - 1 Surgical Oncology Unit, Iasi, Romania
| | - M G Aniței
- "Grigore T. Popa" University of Medicine and Pharmacy - Surgical Department, Iasi, Romania.,Regional Institute of Oncology Iasi - 1 Surgical Oncology Unit, Iasi, Romania
| | - B Filip
- "Grigore T. Popa" University of Medicine and Pharmacy - Surgical Department, Iasi, Romania.,Regional Institute of Oncology Iasi - 1 Surgical Oncology Unit, Iasi, Romania
| | - M Hogea
- Regional Institute of Oncology Iasi - 1 Surgical Oncology Unit, Iasi, Romania
| | - I Radu
- "Grigore T. Popa" University of Medicine and Pharmacy - Surgical Department, Iasi, Romania.,Regional Institute of Oncology Iasi - 1 Surgical Oncology Unit, Iasi, Romania
| | - M M Gavrilescu
- "Grigore T. Popa" University of Medicine and Pharmacy - Surgical Department, Iasi, Romania.,Regional Institute of Oncology Iasi - 1 Surgical Oncology Unit, Iasi, Romania
| | - A Panuță
- "Grigore T. Popa" University of Medicine and Pharmacy - Surgical Department, Iasi, Romania.,Regional Institute of Oncology Iasi - 1 Surgical Oncology Unit, Iasi, Romania
| | - M Buna-Arvinte
- "Grigore T. Popa" University of Medicine and Pharmacy - Surgical Department, Iasi, Romania.,Regional Institute of Oncology Iasi - 1 Surgical Oncology Unit, Iasi, Romania
| | - V G Moraru
- "Grigore T. Popa" University of Medicine and Pharmacy - Surgical Department, Iasi, Romania.,Regional Institute of Oncology Iasi - 1 Surgical Oncology Unit, Iasi, Romania
| | - V Scripcariu
- "Grigore T. Popa" University of Medicine and Pharmacy - Surgical Department, Iasi, Romania.,Regional Institute of Oncology Iasi - 1 Surgical Oncology Unit, Iasi, Romania
| |
Collapse
|